CrystalGenomics Inc (083790) fair value: what the stock is really worth
As of Nov 18, 2026: fair value (intrinsic value) of CrystalGenomics Inc stock KRW 837, price KRW 542, upside +54.4%, quality 43 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
CrystalGenomics Inc
083790 · KQCheap enough by our rule, but weak company and falling price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range 542.00 KRW – 8,480 KRW · fair‑value band 627.54 KRW – 1,046 KRW · the 542.00 KRW price screens below the 836.72 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether CrystalGenomics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea.
Show moreShow less
Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial.
The company's drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus, which is in Phase I clinical trial.
In addition, it offers cloning, expression, purification, and characterization of proteins of interest; and assay and structure services.
The company has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. CrystalGenomics, Inc. was founded in 2000 and is headquartered in Seongnam, South Korea.
Stock analysis
CrystalGenomics Inc (083790) currently trades at 542.00 KRW, while our estimate is 836.72 KRW, so the stock looks roughly fairly valued today (gap 35.2%).
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: 627.54 KRW (bear) to 1,046 KRW (bull), the price of 542.00 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
CrystalGenomics Inc reported revenue of 27.4B KRW in FY2025 versus 42.4B KRW in FY2021, a compound −10.3%/yr. Reported net income was −3.5B KRW in FY2025.
Key figures
Market cap 41.3B KRW (≈ $31.0M) Micro · P/S ratio 1.69 · Dividend yield 3.3% · Net margin −64.6% · Return on equity −4,221% · Return on assets (EBIT) −10.8% (5-year average) · Operating margin −43.3% · Revenue (TTM) 45.0B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (medium confidence).
What moves the price
The share trades about 67% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −34% fair-value upside, at 54%, 083790 screens cheaper than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Watch 083790, get fair value alerts →
Compare CrystalGenomics Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 57 stocks
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- PEG ratio by industry
- Revenue growth by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: South Korean Stocks
- Valuation of the Korea market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Huons Global Co 084110 | 19,300 KRW | 47,019 KRW | +144% | vs 083790 |
| DongKook Pharmaceutical Co 086450 | 24,400 KRW | 28,372 KRW | +16% | vs 083790 |
| ST Pharm Co 237690 | 70,200 KRW | 61,182 KRW | −13% | vs 083790 |
| Vivozon Pharmaceutical Co 082800 | 2,780 KRW | 2,179 KRW | −22% | vs 083790 |
| Oscotec Inc 039200 | 32,300 KRW | 21,262 KRW | −34% | vs 083790 |
| NatureCell Co 007390 | 21,450 KRW | 11,176 KRW | −48% | vs 083790 |
| Mezzion Pharma Co 140410 | 64,800 KRW | 31,450 KRW | −51% | vs 083790 |
| BINEX Co 053030 | 6,850 KRW | 1,844 KRW | −73% | vs 083790 |
| Caregen Co 214370 | 26,600 KRW | 5,414 KRW | −80% | vs 083790 |
| SHUKRAPHAR SHUKRAPHAR | ₹82.23 | ₹9.14 | −89% | vs 083790 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is CrystalGenomics Inc (083790) overvalued or undervalued?
What is the fair value of 083790?
What is the quality score of 083790?
What is the price target for CrystalGenomics Inc (083790)?
What is the CrystalGenomics Inc stock forecast for 2026?
What is the revenue of CrystalGenomics Inc (083790)?
Does CrystalGenomics Inc pay a dividend?
How much is the dividend of CrystalGenomics Inc (083790)?
What is the intrinsic value of CrystalGenomics Inc (083790)?
Is CrystalGenomics Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 083790?
How much is CrystalGenomics Inc worth?
What do the bullish and bearish scenarios say about 083790?
How solid is the balance sheet of CrystalGenomics Inc (083790)?
How far is 083790 from its 52-week high?
Which stocks are comparable to CrystalGenomics Inc?
Is CrystalGenomics Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of CrystalGenomics Inc (083790)?
What should I pay attention to with CrystalGenomics Inc right now?
Key figures of CrystalGenomics Inc
How large is the market capitalisation of CrystalGenomics Inc (083790)?
What is the P/S ratio of CrystalGenomics Inc (083790)?
What is the dividend yield of CrystalGenomics Inc (083790)?
What is the net margin of CrystalGenomics Inc (083790)?
What is the return on equity of CrystalGenomics Inc (083790)?
What is the EBIT return on assets of CrystalGenomics Inc (083790)?
What is the operating margin of CrystalGenomics Inc (083790)?
How fast is revenue growing at CrystalGenomics Inc (083790)?
How much free cash flow does CrystalGenomics Inc (083790) generate?
How much net debt does CrystalGenomics Inc (083790) carry?
Watch CrystalGenomics Inc in the live analysis
One click puts CrystalGenomics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.